Aktienanalyse zu Adagene Inc. (ADAG)ADAGAdagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Adagene Inc (ADAG) is a good buy right now due to its significant upside potential. The current price is $2.29, with an analyst target price of $9, suggesting a potential upside of 166.29%. Additionally, the company's gross margin is an impressive 96.33%, indicating strong profitability on sales. However, the main risk is the negative net income of -4,144,043 USD, reflecting ongoing losses that investors should consider.